Related Experiment Videos
Platelets, aspirin, and cardiovascular disease
P C Elwood1, C Hughes, J R O'Brien
1MRC Epidemiology Unit, Llandough Hospital, Penarth, South Glamorgan, UK.
Postgraduate Medical Journal
|April 22, 1999
Summary
Low-dose aspirin significantly reduces vascular events by one third, potentially preventing 100,000 premature deaths annually. Despite proven benefits and cost-effectiveness, aspirin remains underutilized for cardiovascular prevention.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Public Health
Background:
- Aspirin, synthesized over a century ago, initially served for pain and fever relief.
- Its modern application expanded with trials demonstrating efficacy in secondary prevention of myocardial infarction.
- Overviews of numerous trials have solidified its role in cardiovascular health.
Purpose of the Study:
- To review the evidence for low-dose aspirin in secondary prevention of vascular events.
- To assess the impact of aspirin on mortality and cardiovascular events.
- To highlight the current underutilization of aspirin and its potential for preventing premature deaths.
Main Methods:
- Analysis of randomized controlled trials and meta-analyses of aspirin's effects.
- Inclusion of data from 145 trials in the most recent overview.
- Cost-effectiveness analysis of aspirin therapy.
Main Results:
- Low-dose aspirin reduces vascular events by approximately one third.
- Aspirin therapy is highly cost-effective, saving lives and preventing cardiovascular events.
- Estimated potential to prevent 100,000 premature deaths globally each year.
Conclusions:
- Low-dose aspirin is a proven, cost-effective intervention for secondary cardiovascular prevention.
- Current evidence strongly supports wider aspirin use, yet it remains underutilized.
- Ongoing research explores aspirin's potential in other conditions like vascular dementia and colorectal cancer.